Business Context and Reporting Period
Company: Second Sight Medical Products, Inc. (Note: Request metadata listed "Vivani Medical, Inc.", but the filing text identifies the registrant as Second Sight Medical Products, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: January 7, 2019
Reporting Period: Immediate event reporting regarding a capital raise.
Key Financial Metrics and Capital Structure
This filing details a proposed rights offering rather than standard operating financial results. Key capital metrics include:
- Target Proceeds: Approximately $40.5 million.
- Subscription Price: Lower of $0.98 per unit or the volume-weighted average price of common stock for the five trading days ending February 15, 2019.
- Unit Composition: One share of common stock plus one warrant to purchase one share at a strike price of $1.47.
- Warrant Expiration: Extended to March 14, 2024, if gross proceeds reach at least $20 million; otherwise, warrants expire March 14, 2022.
- Minimum Proceeds: No minimum amount required to close the offering.
Material Changes and Corporate Actions
The primary material change is the entry into a definitive agreement to conduct a rights offering to raise capital. The Company is distributing non-transferable subscription rights to existing common stockholders at no charge. The record date for the offering is January 15, 2019, with an expiration date of February 15, 2019. Gregg Williams, Chairman of the Board, has indicated a non-binding intention to participate with up to $20 million.
Guidance, Outlook, and Use of Proceeds
Management plans to utilize the proceeds from the rights offering for the following strategic initiatives:
- Continuing to gather clinical and performance data to support the safety and efficacy of the Orion® device.
- Completing the development of Argus® 2s (next-generation externals) and seeking regulatory approvals.
- Advancing research in eye-tracking and object recognition.
- General operating and corporate purposes.
Risks and Contingencies: The offering is subject to the expiration of rights on February 15, 2019. If rights are not exercised, they expire with no value. The extension of the warrant term is contingent upon raising at least $20 million.
Investor Verification Checklist
- Verify the record date (January 15, 2019) and settlement requirements to ensure eligibility for the rights offering.
- Confirm the final subscription price, which depends on the volume-weighted average price through February 15, 2019.
- Review the prospectus supplement filed on January 8, 2019, for detailed terms and risk factors.
- Monitor whether the $20 million threshold is met to determine if warrant expiration is extended to 2024.
- Check the trading status of the warrants under the symbol "EYESW" on NASDAQ.